DELTAGEN INC. 
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2002 | 1.77Cr 147.69Cr | Sales 2003 * | - | Capitalization | 1.75Cr 145.97Cr |
|---|---|---|---|---|---|
| Net income 2002 | -11Cr -893.31Cr | Net income 2003 * | - | EV / Sales 2002 | 1.21 x |
| Net Debt 2002 | 17.47L 15Cr | Net cash position 2003 * | - 0 | EV / Sales 2003 * | - |
| P/E ratio 2002 |
-0.17
x | P/E ratio 2003 * |
-
| Employees | - |
| Yield 2002 * |
-
| Yield 2003 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Driscoll
CEO | Chief Executive Officer | - | 01/99/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Driscoll
CEO | Chief Executive Officer | - | 01/99/01 |
Deltagen, Inc. is a provider of drug discovery tools and services to the biopharmaceutical industry. The Company offers a suite of programs designed to manage the efficiency of drug discovery, including access to biological models, as well as both small-molecule and secreted protein drug targets. In addition, it offers target validation data in the areas of immunology and metabolic diseases. The Company's biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Its DeltaBase is a searchable database of in vivo-derived mammalian gene function information and gene targets. DeltaOne from the Company provides per-gene access to the knockout mice and/or phenotypic data needed.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -26.96% | 137.19Cr | |
| -19.77% | 5.61Cr |
